Key result
Tight glycemic control in the first 24 hours after STEMI is discussed as a strategy to reduce scintigraphic infarct size, though infarct size reduction alone often fails to improve clinical outcomes.
Why the study?
Does tight glucose control during the first 24 hours of hospitalization reduce scintigraphic infarct size in STEMI patients?
Does tight glucose control during the first 24 hours of hospitalization reduce scintigraphic infarct size in STEMI patients?
Answers are grounded in this paper and cite their sources.
This editorial highlights the ongoing investigation into whether tight glycemic control post-STEMI can reduce infarct size, while emphasizing that cardioprotection must ultimately translate to improved clinical outcomes rather than just surrogate imaging endpoints.
The infarct size reduction in acute myocardial infarction (AMI) has been studied for more than 50 years. Animal experiments were conducted in the 1970s, followed by the first clinical studies to reduce infarct size (IS), with fibrinolytic agents or with mechanical coronary angioplasty (PTCA). The clinical experience of coronary reperfusion indicated that left ventricle function was not normalized in 30% of the patients, and despite unblocking the epicardial vessel, demonstrated hemodynamically, there was no equivalent in myocardial perfusion. New concepts emerged such as reperfusion injury, microvascular dysfunction, "noreflow" phenomenon, and stunned and hibernating myocardium, which became the focus of basic research and clinical investigation. To improve characterization, different technologies were used, such as contrast echocardiography, isotopic studies, including positron emission tomography, and magnetic resonance.1 Cardioprotection (CP) aims to reduce IS and improve clinical outcomes. The translation of CP from preclinical and promising proof-of-concept studies to clinical benefit (CB) for patients has been quite unsatisfactory. Almost all these studies that did not translate into CB had infarct size reduction as the primary endpoint and used protocols selected to achieve IS reduction.2 In 2001, a pioneering randomized clinical trial (RCT) conducted in Leuven, Belgium, found clear benefits in treating hyperglycemia, supporting a potential causal relationship between hyperglycemia and outcomes. The researchers studied 1548 critically ill patients admitted to a predominantly surgical intensive care unit (ICU), maintaining healthy fasting blood glucose concentrations (80-110 mg/dL), which led to a reduction in morbimortality, compared with tolerance to hyperglycemia up to the renal threshold (215 mg/dL).3 Later, the Leuven’s research group confirmed the clinical benefit in critically ill adults admitted to a clinical ICU (n = 1200) and severely ill children (n = 700). 4,5 Subsequent mechanistic studies attributed the benefit obtained by rigid glucose control to a protection against glucose toxicity and not to glucoseindependent insulin effects.6,7 Despite the promising effects of rigid glucose control in the first controlled studies, the benefit was not confirmed in subsequent multicenter studies and the NICE-SUGAR study found potential damage.7-10 The increased risk of mortality in NICE-SUGAR was subsequently attributed to increased incidence of hypoglycemia.11 This discrepancy can be explained by methodological differences between trials, and not by a different combination of cases. Hyperglycemia (HGL) in the setting of myocardial revascularization (MR) is associated with increased adverse effects in patients with and without diabetes. Data suggest that acute HGL peri-procedure causes increased inflammation, platelet activity, endothelial dysfunction, and is associated with plaque instability and IS. While peri-procedure glycemia is an independent predictor of adverse effects in patients undergoing MR, treatment strategies remain uncertain.12 It is also known that cardioprotective actions of ischemic postconditioning (PCISQ) against ischemia/ reperfusion injury (I/LR) are abolished in diabetic hearts. Several drugs used for treating diabetes have recently shown a reduction in difficult cardiovascular outcomes. Animal studies have sought to investigate the combined effect of PCISQ and these drugs on myocardial function and IS.13 506
No takes yet. Share an insight, caveat, or question.
Lopes et al. (2020) conducted an editorial in ST-elevation myocardial infarction (STEMI) with hyperglycemia. Tight glycemic control vs. Standard glycemic care was evaluated on Myocardial infarct size measured by 99mTc-sestamibi SPECT myocardial perfusion imaging. Tight glycemic control in the first 24 hours after STEMI is discussed as a strategy to reduce scintigraphic infarct size, though infarct size reduction alone often fails to improve clinical outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: